J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kearney, B. P.
Right arrow Articles by Cheng, A. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kearney, B. P.
Right arrow Articles by Cheng, A. K.

PHARMACOKINETICS

Drug-Drug and Drug-Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine

Brian P. Kearney, PharmD, John R. Sayre, RN, John F. Flaherty, PharmD, Shan-Shan Chen, MPH, Sanjeev Kaul, PhD and Andrew K. Cheng, MD, PhD

From Gilead Sciences, Inc, Foster City, California (Dr Kearney, Mr Sayre, Dr Flaherty, Mr Chen, Dr Cheng); and Bristol-Myers Squibb Co, Princeton, New Jersey (Dr Kaul).

The drug-drug and drug-food interactions between tenofovir DF and didanosine EC were evaluated in 2 pharmacokinetic studies in healthy adult subjects. When 400 mg was dosed with tenofovir DF, mean didanosine AUC was increased by 44% to 60% following fasted or fed administration. Staggered coadministration (2 hour, fasted) of a reduced didanosine dose of 250 mg resulted in equivalent didanosine exposure, while simultaneous administration with tenofovir DF in the fasted and fed state resulted in didanosine AUCs similar to that of the reference treatment of 400 mg alone in the fasted state. These data indicate that a dose reduction of didanosine is warranted when it is used with tenofovir DF. The drug-drug-food interaction of didanosine may offer more flexible dosing of didanosine EC when it is used with tenofovir DF. Patients receiving tenofovir DF and didanosine together should be carefully monitored for safety and efficacy.

Key Words: Tenofovir DF • didanosine EC • pharmacokinetics • drug interaction • HIV

Address for reprints: Brian P. Kearney, PharmD, Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
L. A. Wenning, E. J. Friedman, J. T. Kost, S. A. Breidinger, J. E. Stek, K. C. Lasseter, K. M. Gottesdiener, J. Chen, H. Teppler, J. A. Wagner, et al.
Lack of a Significant Drug Interaction between Raltegravir and Tenofovir
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3253 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
A. D. Luber
Pharmacokinetic Considerations for Selection of HAART in Treatment-Naive HIV-Infected Individuals, 2008: More Than It Seems?
J Int Assoc Physicians AIDS Care (Chic Ill), March 1, 2008; 7(1_suppl): 10 - 16.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Weiss, D. Theile, N. Ketabi-Kiyanvash, H. Lindenmaier, and W. E. Haefeli
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors
Drug Metab. Dispos., March 1, 2007; 35(3): 340 - 344.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Clinical Pharmacology